CN102036713A - 涉及呼吸障碍的方法 - Google Patents

涉及呼吸障碍的方法 Download PDF

Info

Publication number
CN102036713A
CN102036713A CN2008801244097A CN200880124409A CN102036713A CN 102036713 A CN102036713 A CN 102036713A CN 2008801244097 A CN2008801244097 A CN 2008801244097A CN 200880124409 A CN200880124409 A CN 200880124409A CN 102036713 A CN102036713 A CN 102036713A
Authority
CN
China
Prior art keywords
ep3r
mpges
test substance
level
pge
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801244097A
Other languages
English (en)
Chinese (zh)
Inventor
E·赫勒尼斯
P-J·雅各布森
A·霍夫施泰特罗森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samsara Medicin AB
Original Assignee
Samsara Medicin AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsara Medicin AB filed Critical Samsara Medicin AB
Publication of CN102036713A publication Critical patent/CN102036713A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
    • Y10T436/201666—Carboxylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2008801244097A 2007-11-12 2008-11-12 涉及呼吸障碍的方法 Pending CN102036713A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98721707P 2007-11-12 2007-11-12
US60/987,217 2007-11-12
PCT/GB2008/003856 WO2009063226A2 (en) 2007-11-12 2008-11-12 Methods relating to breathing disorders

Publications (1)

Publication Number Publication Date
CN102036713A true CN102036713A (zh) 2011-04-27

Family

ID=40342124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801244097A Pending CN102036713A (zh) 2007-11-12 2008-11-12 涉及呼吸障碍的方法

Country Status (6)

Country Link
US (1) US20110008258A1 (enExample)
EP (1) EP2219736A2 (enExample)
JP (1) JP2011503164A (enExample)
CN (1) CN102036713A (enExample)
CA (1) CA2743334A1 (enExample)
WO (1) WO2009063226A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107864617A (zh) * 2015-03-19 2018-03-30 启迪医疗仪器公司 用于治疗睡眠障碍性呼吸的刺激
CN108290019A (zh) * 2015-12-01 2018-07-17 皇家飞利浦有限公司 处置共济失调性呼吸的方法和设备
CN113376386A (zh) * 2020-03-09 2021-09-10 中国科学院广州生物医药与健康研究院 一种病毒性肺炎的标志物及其应用
CN115624626A (zh) * 2022-08-15 2023-01-20 山东大学齐鲁医院 Ep3受体在脊髓损伤后神经源性膀胱防治中的应用
CN117323320A (zh) * 2023-11-20 2024-01-02 复旦大学附属中山医院 长链脂肪酸12-hht在睡眠呼吸暂停合并高血压中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101446873B1 (ko) 2013-06-14 2014-10-06 서울대학교산학협력단 수면 무호흡증 진단용 생체 표지자 및 그 용도
US20160124002A1 (en) * 2013-06-14 2016-05-05 Seoul National University R&Db Foundation Method for detecting hypoxia or diagnosing hypoxia-related diseases
US11103159B2 (en) 2016-03-04 2021-08-31 United States Of America As Represented By The Secretary Of The Air Force Exhaled breath hypoxia biomarkers
AU2019335070A1 (en) * 2018-09-06 2021-05-13 Ian Cooke Method of treating a sleep breathing disorder

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000175A2 (en) * 2000-06-28 2002-01-03 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
WO2002005799A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
WO2004011613A2 (en) * 2002-07-29 2004-02-05 Epigenesis Pharmaceuticals, Inc. Composition & methods for treatment and screening
WO2004078113A2 (en) * 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
WO2005009340A2 (en) * 2003-07-24 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
WO2005053669A1 (fr) * 2003-12-01 2005-06-16 Pierre Fabre Medicament Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
WO2006019984A2 (en) * 2004-07-15 2006-02-23 Yale University Compositions, methods and kits for the diagnosis and treatment of sudden infant death syndrome
EP1629850A1 (en) * 2004-08-24 2006-03-01 Nutricia N.V. Nutritional composition comprising indigestible oligosaccharides
WO2006033965A2 (en) * 2004-09-16 2006-03-30 The Trustees Of The University Of Pennsylvania Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US20060194840A1 (en) * 2003-09-19 2006-08-31 David Gozal Method for treating snoring and sleep apnea with leukotriene antagonists
WO2007038705A2 (en) * 2005-09-28 2007-04-05 Medtronic, Inc. Methods for detecting and monitoring sleep disordered breathing using an implantable medical device
WO2007047372A2 (en) * 2005-10-14 2007-04-26 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074896A1 (en) * 2006-11-30 2010-03-25 The Johns Hopkins University Antagonists of pge2 ep3 receptors
US8071557B2 (en) * 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000175A2 (en) * 2000-06-28 2002-01-03 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
WO2002005799A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
WO2004011613A2 (en) * 2002-07-29 2004-02-05 Epigenesis Pharmaceuticals, Inc. Composition & methods for treatment and screening
WO2004078113A2 (en) * 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
WO2005009340A2 (en) * 2003-07-24 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
US20060194840A1 (en) * 2003-09-19 2006-08-31 David Gozal Method for treating snoring and sleep apnea with leukotriene antagonists
WO2005053669A1 (fr) * 2003-12-01 2005-06-16 Pierre Fabre Medicament Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
WO2006019984A2 (en) * 2004-07-15 2006-02-23 Yale University Compositions, methods and kits for the diagnosis and treatment of sudden infant death syndrome
EP1629850A1 (en) * 2004-08-24 2006-03-01 Nutricia N.V. Nutritional composition comprising indigestible oligosaccharides
WO2006033965A2 (en) * 2004-09-16 2006-03-30 The Trustees Of The University Of Pennsylvania Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
WO2007038705A2 (en) * 2005-09-28 2007-04-05 Medtronic, Inc. Methods for detecting and monitoring sleep disordered breathing using an implantable medical device
WO2007047372A2 (en) * 2005-10-14 2007-04-26 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
B HOCH，ET AL,: "Central apnoea and endogenous prostaglandins in neonates", 《ACTA PAEDIATRICA》 *
BETH S. FRIEDMAN, ET AL,: "Oral Leukotriene Inhibitor (MK-886) Blocks Allergen-induced Airway Responses", 《AMERICAN REVIEW OF RESPIPATORY DISEASE》 *
HE´ LE`NE JUTEAU, ET AL,: "Structure–Activity Relationship of Cinnamic Acylsulfonamide Analogues on the Human EP3 Prostanoid Receptor", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
HOFSTETTER ET AL.: "The induced prostaglandin E2 pathway is a key regulator of the respiratory response to infection and hypoxia in neonates", 《PNAS》 *
JM VILANOVA1, ET AL,: "Arachidonic acid metabolites in CSF in hypoxic-ischaemic encephalopathy of newborn infants", 《ACTA PAEDIATRICA》 *
PIETRO CAIRONI, ET AL,: "5-Lipoxygenase Deficiency Prevents Respiratory Failure during Ventilator-induced Lung Injury", 《AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE》 *
RICHARD C. LI, ET AL,: "Cyclooxygenase 2 and Intermittent Hypoxia-induced Spatial Deficits in the Rat", 《AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107864617A (zh) * 2015-03-19 2018-03-30 启迪医疗仪器公司 用于治疗睡眠障碍性呼吸的刺激
CN108290019A (zh) * 2015-12-01 2018-07-17 皇家飞利浦有限公司 处置共济失调性呼吸的方法和设备
CN113376386A (zh) * 2020-03-09 2021-09-10 中国科学院广州生物医药与健康研究院 一种病毒性肺炎的标志物及其应用
WO2021179555A1 (zh) * 2020-03-09 2021-09-16 中国科学院广州生物医药与健康研究院 一种病毒性肺炎的标志物及其应用
CN113376386B (zh) * 2020-03-09 2025-09-02 中国科学院广州生物医药与健康研究院 一种病毒性肺炎的标志物及其应用
CN115624626A (zh) * 2022-08-15 2023-01-20 山东大学齐鲁医院 Ep3受体在脊髓损伤后神经源性膀胱防治中的应用
CN115624626B (zh) * 2022-08-15 2024-04-09 山东大学齐鲁医院 Ep3受体在脊髓损伤后神经源性膀胱防治中的应用
CN117323320A (zh) * 2023-11-20 2024-01-02 复旦大学附属中山医院 长链脂肪酸12-hht在睡眠呼吸暂停合并高血压中的应用

Also Published As

Publication number Publication date
WO2009063226A3 (en) 2010-01-07
EP2219736A2 (en) 2010-08-25
JP2011503164A (ja) 2011-01-27
US20110008258A1 (en) 2011-01-13
CA2743334A1 (en) 2009-05-22
WO2009063226A2 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
Parikh et al. Cellular senescence in the lung across the age spectrum
CA2743334A1 (en) Methods relating to breathing disorders
Hayashi et al. Hypoxia‐sensitive molecules may modulate the development of atherosclerosis in sleep apnoea syndrome
Bueno et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis
Mishra et al. Contribution of sodium channel neuronal isoform Nav1. 1 to late sodium current in ventricular myocytes from failing hearts
Tu et al. Long noncoding NONRATT021972 siRNA normalized abnormal sympathetic activity mediated by the upregulation of P2X7 receptor in superior cervical ganglia after myocardial ischemia
Betrie et al. Evidence of a cardiovascular function for microtubule-associated protein tau
Herlenius An inflammatory pathway to apnea and autonomic dysregulation
Shen et al. IL-33/ST2 mediating systemic inflammation and neuroinflammation through NF-kB participated in the neurocognitive impairment in obstructive sleep apnea
Zuo et al. Isoflurane anesthesia in aged mice and effects of A1 adenosine receptors on cognitive impairment
Zhou et al. sFRP2 promotes airway inflammation and Th17/Treg imbalance in COPD via Wnt/β-catenin pathway
JP2022517117A (ja) Ｓｔｍｎ２レベルを回復させるための方法及び組成物
US20180318285A1 (en) Methods for treatment of autism spectrum disorders
Song et al. Acid-sensing ion channels are expressed in the ventrolateral medulla and contribute to central chemoreception
Quatredeniers et al. Functional interaction between PDGFβ and GluN2B-containing NMDA receptors in smooth muscle cell proliferation and migration in pulmonary arterial hypertension
Yin et al. Chronic cocaine induces HIF-VEGF pathway activation along with angiogenesis in the brain
Mi et al. Alterations of electrophysiological properties and ion channel expression in prefrontal cortex of a mouse model of schizophrenia
JP2011503164A5 (enExample)
Lee et al. Effects of urate-lowering agents on arrhythmia vulnerability in post-infarcted rat hearts
Pan et al. Reduced ULK1 links impaired autophagy and mitophagy to Alzheimer’s disease pathology
Lu et al. Inhibition of Wnt/β‐catenin signaling upregulates Nav1. 5 channels in Brugada syndrome iPSC‐derived cardiomyocytes
Zhang et al. Pontine norepinephrine defects in Mecp2-null mice involve deficient expression of dopamine β-hydroxylase but not a loss of catecholaminergic neurons
Xin et al. E2F2 induces microglial activation and augments depressive-like behavior in mice by repressing PTPN6 transcription
Wickström et al. Hypoxic response in newborn rat is attenuated by neurokinin-1 receptor blockade
HK1157267A (en) Methods relating to breathing disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1157267

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110427

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1157267

Country of ref document: HK